These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 15500417)

  • 1. Arsenic trioxide in the treatment of haematological malignancies.
    Kwong YL
    Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide: safety issues and their management.
    Au WY; Kwong YL
    Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
    Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
    Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
    Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
    Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide.
    Litzow MR
    Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
    Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    Liu P; Han ZC
    Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
    Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
    Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In the war against solid tumors arsenic trioxide needs partners.
    Subbarayan PR; Ardalan B
    J Gastrointest Cancer; 2014 Sep; 45(3):363-71. PubMed ID: 24825822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide - An old drug rediscovered.
    Emadi A; Gore SD
    Blood Rev; 2010; 24(4-5):191-9. PubMed ID: 20471733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
    Iland HJ; Wei A; Seymour JF
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
    Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
    Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.